Indoco Remedies opened with a gain of 8% at Rs.282 and rose almost 9% to hit an intraday high at Rs.284.10. Its 52-week high is at Rs.295, hit on 17th Sept’20.
The company, on Saturday, announced the launch of FEVINDO (Favipiravir) 400 mg Tablets in India. Fevindo ? 400 (Favipiravir) is an antiviral drug, effective against the RNA?based influenza virus. The drug has been approved by DCGI in the treatment of Covid?19.
Fevindo 400 reduces pill burden by 50% and ensures convenient dosing and better patient compliance.
Fevindo ? 400 (Favipiravir) will be made available at all government approved COVID care centres and selected medical practitioners across the country.
In addition to Fevindo, Indoco has two more new products for launch in Covid Care range, i.e., Povidone Iodine Gargle and Immunity booster chewable tablets with Zinc, Vitamin C and Vitamin D.
A fortnight ago, it had received approval from the US FDA for blood-thinning drug Apixaban tablets. Reinstatement of the EU-GMP compliance certificate for Goa Plant-I and the EU-GMP approval of newly acquired solid dosages manufacturing facility at Baddi (Plant-III) will boost the EU business, with the availability of larger manufacturing capacity.